Guggenheim Capital
BEAM icon

Guggenheim Capital’s Beam Therapeutics BEAM Stock Holding History

Guggenheim Capital’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.17M Sell
34,091
-1,793
-5% -$54.1K 0.01% 960
2026
Q1 		$855K Buy
35,884
+6,376
+22% +$177K 0.01% 1039
2025
Q4 		$818K Buy
29,508
+1,032
+4% +$26.3K 0.01% 1041
2025
Q3 		$691K Sell
28,476
-5,255
-16% -$105K 0.01% 1057
2025
Q2 		$574K Sell
33,731
-5,918
-15% -$103K ﹤0.01% 1113
2025
Q1 		$774K Buy
39,649
+3,822
+11% +$100K 0.01% 991
2024
Q4 		$889K Sell
35,827
-6,818
-16% -$174K 0.01% 973
2024
Q3 		$1.04M Sell
42,645
-4,434
-9% -$115K 0.01% 1079
2024
Q2 		$1.1M Sell
47,079
-1,316
-3% -$32.3K 0.01% 1073
2024
Q1 		$1.6M Sell
48,395
-3,208
-6% -$99.9K 0.01% 975
2023
Q4 		$1.4M Sell
51,603
-18,390
-26% -$457K 0.01% 993
2023
Q3 		$1.68M Sell
69,993
-16,349
-19% -$438K 0.01% 873
2023
Q2 		$2.76M Buy
86,342
+5,104
+6% +$166K 0.02% 729
2023
Q1 		$2.49M Sell
81,238
-6,620
-8% -$261K 0.02% 775
2022
Q4 		$3.44M Buy
87,858
+328
+0.4% +$14.7K 0.03% 655
2022
Q3 		$4.17M Sell
87,530
-9,409
-10% -$537K 0.04% 577
2022
Q2 		$3.75M Buy
96,939
+5,603
+6% +$223K 0.03% 663
2022
Q1 		$5.23M Buy
91,336
+2,182
+2% +$143K 0.03% 633
2021
Q4 		$7.1M Buy
89,154
+16,846
+23% +$1.44M 0.04% 544
2021
Q3 		$6.29M Buy
72,308
+47,463
+191% +$4.77M 0.04% 565
2021
Q2 		$3.2M Buy
+24,845
New +$1.98M 0.02% 853

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Farallon Capital Management
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Nikko Asset Management Americas
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Guggenheim Capital's BEAM Position: Q2 2026 in Review

Guggenheim Capital reduced its Beam Therapeutics (BEAM) stake by 5% in Q2 2026, selling an estimated $54.1K and leaving 34,091 shares worth $1.17M. The position accounts for 0.01% of the portfolio, ranked #960.

Guggenheim Capital first reported a position in BEAM in Q2 2021 and has held it in 21 quarters since. The position peaked at $7.1M in Q4 2021. 277 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

  • Guggenheim Capital held 34,091 shares of Beam Therapeutics worth $1.17M as of Q2 2026.
  • Guggenheim Capital sold 1,793 Beam Therapeutics shares in Q2 2026, an estimated $54.1K.
  • Beam Therapeutics made up 0.01% of Guggenheim Capital's portfolio in Q2 2026, its #960 holding.
  • Guggenheim Capital first reported a position in Beam Therapeutics in Q2 2021 and has held it in 21 quarters since.
  • Guggenheim Capital's Beam Therapeutics position peaked at $7.1M in Q4 2021.
  • 277 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on Guggenheim Capital's 13F filing for Q2 2026, filed 12 Aug 2026.